This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Tuesday's Health Winners & Losers

Health care stocks edged up on analysts' actions and regulatory approvals Tuesday, though disappointing earnings tempered gains.

After PDL BioPharma (PDLI) said Monday that CEO Mark McDade would leave by the end of the year, despite being cleared in an internal investigation, First Albany upgraded the stock to buy from neutral. Shares continued to climb Tuesday, gaining 72 cents, or 3.1%, to $23.64.

First Albany also downgraded Adams Respiratory Therapeutics (ARXT) to buy from strong buy, and upped its price target for Myriad Genetics (MYGN) to $49 from $44.

Adams reported a loss of $1 million, or 3 cents a share, compared to a profit of $6.4 million, or 17 cents a share, in the year-ago period. It surpassed expectations of analysts polled by Thomson Financial, who predicted a loss of 4 cents per share. However, it guided below the consensus estimate for 2008. The company sees earnings of between $1.55 and $1.75 a share, vs. analysts' expectation of $1.84 a share. Shares gave up $4.62 or 11.4%, to $36.10.

Myriad lost $7.8 million, or 18 cents a share, compared with a loss of $11.4 million, or 29 cents a share, in the year-ago period. Revenue rose to $45.5 million from $32 million. Analysts expected a loss of 19 cents a share on revenue of $42.9 million. But shares still edged down $1.09, or 2.5%, to $42.03.

Adams and Myriad are both components of the Nasdaq Biotechnology index, which was up 1.88, or 0.22%, to 799.96.

DJO (DJO) gained 1% after saying it received FDA approval for new features for its existing bone growth stimulation devices. The new features will make the products easier to use. The stock was up 49 cents to $47.91.

St. Jude (STJ) said it received approval from Japan's Ministry of Health, Labor and Welfare, for its Angio-Seal STS Plus Vascular Closure device. The company also received reimbursement approval for the device in Japan. Shares were up 7 cents to $43.33.

Genta (GNTA) gained 6.3%, after it said it enrolled its first patients in AGENDA, its phase III trial for Genasense Injection treatment for advanced melanoma. The company plans to accrue 300 patients worldwide in about 18 months. Shares rose 5 cents to 85 cents.

Elsewhere, Encysive Pharmaceuticals (ENCY) said it would sell 7.7 million shares to institutional investors for $1.95 a share. The offering is expected to raise $15 million in proceeds, before fees and expenses. The company also will issue five-year warrants to purchase 7.7 million shares at the same exercise price. The company will use the $15 million for working capital and general corporate purposes, including commercialization of hypertension drug Thelin in Europe, Canada and Australia.

The company expects to close the offering or before Friday. Shares slipped 14 cents, or 7.1%, to $1.84.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs